MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$26,550K
Net Income
-$91,800K
Net Profit Margin
-345.76%
EPS
-$3.59
Unit: Thousand (K) dollars
Revenue Breakdown
Product
License Royalty And Other
Service
Revenue Breakdown
Degenerative Disease
Biobanking
Cell Therapy
Subscribe for Financial Insights
Page 1
Annual
123
Page 1
Income Statement
2025-12-31
Total revenues
26,550
Change in fair value of contingent consideration liability
0
Research and development
15,025
Selling, general and administrative
51,266
Amortization of acquired intangible assets
1,493
Cost of revenues
20,074
Total operating expenses
87,858
Loss from operations
-61,308
Interest income
262
Interest expense
6,754
Change in fair value of warrant liabilities
3,318
Change in fair value of derivative liability
65
Change in fair value of debt
1,809
Loss on debt extinguishment
-6,356
Amortization of licensing obligation premium
1,911
Loss on issuance of convertible notes with warrants
-2,335
Impairment of preferred stock investment
2,890
Compliance fees and other expense, net
-9,181
Total other expense
-30,405
Loss before income taxes
-91,713
Income tax expense (benefit)
3
Net loss
-91,716
Deemed dividend relating to inducement of dragasac warrants
64
Paid-in kind preferred stock dividend
20
Net loss attributable to common shareholders
-91,800
Basic EPS
-3.59
Diluted EPS
-3.59
Basic Average Shares
25,598,586
Diluted Average Shares
25,598,586
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS).
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
1
2
Net loss
attributable to common...
-$91,800K
Net loss
-$91,716K
Deemed dividend
relating to inducement of...
$64K
Paid-in kind preferred
stock dividend
$20K
Loss before income
taxes
-$91,713K
Income tax expense
(benefit)
$3K
Product
$13,175K
License Royalty And
Other
$7,943K
Service
$5,432K
Loss from operations
-$61,308K
Total other expense
-$30,405K
Total revenues
$26,550K
Amortization of licensing
obligation premium
$1,911K
Interest income
$262K
Change in fair value of
derivative liability
$65K
Total operating
expenses
$87,858K
Compliance fees and other
expense, net
-$9,181K
Interest expense
$6,754K
Loss on debt
extinguishment
-$6,356K
Change in fair value of
warrant liabilities
$3,318K
Impairment of preferred
stock investment
$2,890K
Loss on issuance of
convertible notes with...
-$2,335K
Change in fair value of
debt
$1,809K
Selling, general and
administrative
$51,266K
Cost of revenues
$20,074K
Research and development
$15,025K
Amortization of acquired
intangible assets
$1,493K
Buy us a coffee
Celularity Inc (CELU)
Celularity Inc (CELU)